Haemonetics (NYSE:HAE) Reaches New 12-Month Low - Here's Why

Key Points

• Haemonetics Corporation's stock has reached a new 12-month low, trading as low as $49.16 during the recent trading session.
• Despite the drop, analysts remain cautiously optimistic, with a consensus rating of "Moderate Buy" and varying price targets ranging from $62.00 to $90.00.
• The company reported a quarterly earnings beat but experienced a revenue decline of 4.4% compared to the previous year, giving a FY 2026 guidance of 4.700-5.00 EPS.

Haemonetics Corporation (NYSE:HAE - Get Free Report) reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $49.38 and last traded at $49.16, with a volume of 127918 shares traded. The stock had previously closed at $50.61.

Wall Street Analyst Weigh In

HAE has been the topic of several analyst reports. Baird R W raised shares of Haemonetics to a "strong-buy" rating in a research report on Wednesday, June 25th. Citigroup raised shares of Haemonetics from a "neutral" rating to a "buy" rating and set a $90.00 price target on the stock in a research report on Wednesday, July 9th. JPMorgan Chase & Co. reaffirmed a "neutral" rating and set a $62.00 price target (down from $85.00) on shares of Haemonetics in a research report on Friday, August 8th. Raymond James Financial lowered shares of Haemonetics from a "strong-buy" rating to an "outperform" rating and dropped their price target for the stock from $105.00 to $78.00 in a research report on Monday, August 11th. Finally, Robert W. Baird initiated coverage on shares of Haemonetics in a research report on Thursday, June 26th. They set an "outperform" rating and a $87.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Haemonetics currently has a consensus rating of "Moderate Buy" and a consensus target price of $78.78.

Haemonetics Stock Performance

The stock has a market capitalization of $2.34 billion, a price-to-earnings ratio of 14.87, a P/E/G ratio of 0.93 and a beta of 0.39. The company's fifty day simple moving average is $59.73 and its 200 day simple moving average is $64.53. The company has a quick ratio of 1.04, a current ratio of 1.72 and a debt-to-equity ratio of 1.04.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 EPS for the quarter, beating the consensus estimate of $1.01 by $0.09. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The business had revenue of $321.39 million for the quarter, compared to the consensus estimate of $305.12 million. During the same period in the prior year, the company posted $1.02 earnings per share. Haemonetics's revenue was down 4.4% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. On average, equities research analysts expect that Haemonetics Corporation will post 4.55 earnings per share for the current year.

Hedge Funds Weigh In On Haemonetics

Several institutional investors and hedge funds have recently modified their holdings of HAE. Quarry LP grew its stake in Haemonetics by 63.4% during the first quarter. Quarry LP now owns 495 shares of the medical instruments supplier's stock worth $31,000 after buying an additional 192 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in Haemonetics by 2,640.0% during the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier's stock worth $31,000 after buying an additional 396 shares in the last quarter. GAMMA Investing LLC grew its stake in Haemonetics by 59.4% during the second quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier's stock worth $33,000 after buying an additional 165 shares in the last quarter. UMB Bank n.a. grew its stake in Haemonetics by 91.7% during the second quarter. UMB Bank n.a. now owns 669 shares of the medical instruments supplier's stock worth $50,000 after buying an additional 320 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC acquired a new stake in Haemonetics during the second quarter worth about $64,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.